LH vs RL
LH: A global diagnostics and drug development laboratory leader that performs 750+ million clinical tests annually and supports 85% of new FDA-approved drugs through comprehensive testing capabilities. RL: A global luxury lifestyle brand built on nearly 60 years of timeless design, selling fashion, accessories, home, and fragrances through retail, wholesale, and licensing across 100+ countries.
Side-by-side fundamentals
| Metric | LH | RL | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $281.46 | $387.14 | |
| Market cap as of 2026-07-23 | $23.1B | $23.0B | |
| P/E as of 2026-07-23 | 24.51 | 24.42 | RL lower |
| PEG as of 2026-07-23 | 2.76 | 2.71 | RL lower |
| Net margin as of 2026-07-23 | +6.7% | +11.6% | RL higher |
| Gross margin as of 2026-07-23 | +28.8% | +69.9% | RL higher |
| Operating margin as of 2026-07-23 | +10.2% | +14.5% | RL higher |
| ROE as of 2026-07-23 | +10.9% | +34.8% | RL higher |
| ROA as of 2026-07-23 | +5.1% | +12.3% | RL higher |
| Debt / equity as of 2026-07-23 | 0.73 | 0.52 | RL lower |
| Revenue growth (YoY) as of 2026-07-23 | +7.3% | +14.6% | RL higher |
| Revenue CAGR (3y) SEC XBRL | +5.6% | +8.0% | RL higher |
| Dividend yield as of 2026-07-23 | +1.0% | +1.0% | RL higher |
| Dividend streak (yrs) SEC XBRL | 4 | 5 | RL higher |
| Beta as of 2026-07-23 | 0.88 | 1.38 | |
| 1-year return as of 2026-07-22 close | +11.7% | +34.3% | RL higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.